

**CÔNG TY** 

## AGENDA OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS **IMEXPHARM CORPORATION**

CP DUOFINE AND AM, Friday, April 25, 2025

NOO	TIME	DETAILS
1.	7:45 – 8:30	Shareholder's registration and guest welcoming
2.	8:30 - 8:35	Opening ceremony and introducing delegates
3.	8:35 - 8:40	Report on shareholder's verification
4.	8:40 - 8:45	Approval of Meeting Agenda
5.	8:45 – 8:50	Approval of the working rules of Annual General Meeting of Shareholders 2025
		Introduction to the Presidium, the Secretariat
6.	8:50 - 8:55	Approval of the Vote Checking Committee
7.	8:55 - 9:00	CONNECTING SCIENCE - RESILIENT GROWTH (Video Presentation)
	0.00 0.00	CORPORATE GOVERNANCE LINKED TO SUSTAINABLE DEVELOPMENT
	9:00 – 9:10	<ul> <li>Standardized, Transparent, Efficient, and Sustainable Corporate Governance.</li> </ul>
8.		
		<ul> <li>Aiming to become Vietnam's No.1 Pharmaceutical Company in ESG practices.</li> <li>(BOD Chairperson's Report)</li> </ul>
		SAFE AND EFFICIENT OPERATIONS
9.	9:10 – 9:18	
		Enhancing internal control, risk management, and compliance aligned with international standards.
		(Report by Independent Board Member, Chairperson of the Audit Committee)
	9:18 – 9:33	HIGH-VALUE PRODUCTS, LEADING IN GROWTH
		Overview of Vietnam Pharmaceutical Market and IMP in 2024  Market and IMP in 2024
10.		<ul> <li>Market expansion and diversification of high-value product portfolio based of technology and DOD.</li> </ul>
		technology and R&D
		<ul> <li>Leading listed pharmaceutical companies in growth rate and charter capital size.</li> </ul>
		(General Director Report)
11.	9:33 – 9:41	INNOVATION AND TECHNOLOGY APPLICATION
		<ul> <li>Optimizing operations through technology application and digital transformation</li> </ul>
		aligned with international standards.
		Robust financial position providing strong support for resilient growth.
		<ul> <li>Investment and expansion: leading market-oriented pharmaceutical company</li> </ul>
		focusing on high-value products and advanced technologies.
		(Deputy General Director – CFO Report)
	9:41 – 10:11	VOTING
		a. Approval of proposals:
		The 2024 Audited Financial Statements
		2. Profit distribution plan and dividend for 2024; Dividend plan for 2025
		3. Remuneration of the Board of Directors for 2025
		4. Selection of an auditing firm for the fiscal year 2025
		5. Proposal on Supplementing the Business Lines of the Company
12.		6. Proposal on Adjusting the Maximum Foreign Ownership Limit (FOL) in Imexpharn
		Corporation
		7. Proposal on amendments and supplements to the Company's Charter
		8. Proposal on amendments and supplements to the Internal Regulations on
		Corporate Governance
		9. Other issues (if any).
		b. Voting instructions
		c. Conducting the voting process
13.	10:11 – 10:26	Coffee break
14.	10:26 - 10:56	Discussion - Q&A
15.	10:56 – 11:01	Declaration of voting results
16.	11:01 - 11:06	Approval of the Resolutions and Meeting Minutes